华讯
/
最新消息
所属分类概要描述: 1
辞旧迎新,关怀送暖 省市台办领导走访慰问莅临华讯平台
辞旧迎新,关怀送暖  省市台办领导走访慰问莅临华讯平台
辞旧迎新,关怀送暖 省市台办领导走访慰问莅临华讯平台   在新春佳节来临之际,为进一步增进台胞台商的情感交流,1月19日,江苏省台办副主任吴伟荣一行来到华讯国际知识产权与涉外法律服务平台走访看望台胞台商,市台办副主任李芬琴、联络处处长哈赵刚,江北新区宣传和统战部副部长杨涛,研创园相关负责人陪同参加。   由「南京华讯知识产权顾问有限公司」(以下简称「南京华讯」)副总经理李悦宁女士负责接待各位领导并重点参观了南京华讯及庆辰法律事务所驻南京代表处,期间更关怀企业台胞、员工的春节过年计划,提前致以节日的祝福和亲切的问候。 李悦宁女士汇报了华讯成立历史、团队背景资历、经营情况、典型案例、发展前景等情况,座谈会上,江苏省台办吴副主任了解到在疫情防控常态化及全球经济下行等不利因素影响下,企业的发展情况,嘱咐南京华讯负责人要做好防护工作,保护好自身安全,同时双方还就当下知识产权行业市场现状进行了深入交流。由于,南京华讯于2014年初正式运营。当年度即荣获「江苏省民营科技企业」称号,2016年更获得「江苏省科技型中小企业」称号。南京华讯经营的高阶知识产权信息与顾问服务,在重要科技及医疗产业所涉及的知识产权与涉法项目,均能提供企业所需之资源与解决方案,鉴于,中国与美国是世界上最主要的两大市场,南京华讯更将研究的知识产权着重在中国与美国的专利。并同步扩张到日本与欧洲。南京华讯的重要合作伙伴南京庆辰,更是江苏省与南京市自贸区第一家境外法律事务所,从筹办到取证,南京庆辰得获肯定,有此殊荣。南京华讯与南京庆辰的合作交流,让企业在知识产权议题与涉法项目上,能得到更全方位的专业服务。 南京华讯除了希望为未来进入江苏的台资企业树立榜样,发挥自身为桥梁的作用,更期盼能引导更多台胞人才来江苏投资兴业,为江苏的企业发展奉献一份力。
查看详情
辞旧迎新,关怀送暖 省市台办领导走访慰问莅临华讯平台   在新春佳节来临之际,为进一步增进台胞台商的情感交流,1月19日,江苏省台办副主任吴伟荣一行来到华讯国际知识产权与涉外法律服务平台走访看望台胞台商,市台办副主任李芬琴、联络处处长哈赵刚,江北新区宣传和统战部副部长杨涛,研创园相关负责人陪同参加。   由「南京华讯知识产权顾问有限公司」(以下简称「南京华讯」)副总经理李悦宁女士负责接待各位领导并重点参观了南京华讯及庆辰法律事务所驻南京代表处,期间更关怀企业台胞、员工的春节过年计划,提前致以节日的祝福和亲切的问候。 李悦宁女士汇报了华讯成立历史、团队背景资历、经营情况、典型案例、发展前景等情况,座谈会上,江苏省台办吴副主任了解到在疫情防控常态化及全球经济下行等不利因素影响下,企业的发展情况,嘱咐南京华讯负责人要做好防护工作,保护好自身安全,同时双方还就当下知识产权行业市场现状进行了深入交流。由于,南京华讯于2014年初正式运营。当年度即荣获「江苏省民营科技企业」称号,2016年更获得「江苏省科技型中小企业」称号。南京华讯经营的高阶知识产权信息与顾问服务,在重要科技及医疗产业所涉及的知识产权与涉法项目,均能提供企业所需之资源与解决方案,鉴于,中国与美国是世界上最主要的两大市场,南京华讯更将研究的知识产权着重在中国与美国的专利。并同步扩张到日本与欧洲。南京华讯的重要合作伙伴南京庆辰,更是江苏省与南京市自贸区第一家境外法律事务所,从筹办到取证,南京庆辰得获肯定,有此殊荣。南京华讯与南京庆辰的合作交流,让企业在知识产权议题与涉法项目上,能得到更全方位的专业服务。 南京华讯除了希望为未来进入江苏的台资企业树立榜样,发挥自身为桥梁的作用,更期盼能引导更多台胞人才来江苏投资兴业,为江苏的企业发展奉献一份力。
Advanced Version of New Antibiotics-Antimicrobial Peptide
Advanced Version of New Antibiotics-Antimicrobial Peptide
Advanced Version of New Antibiotics-Antimicrobial Peptide   In 1929, British bacteriologist Fleming discovered penicillin for the first time. Since then, Antibiotics have officially entered the stage of history. During the Second World War, penicillin became a very important strategic material to prevent war wounds from being infected. However, with the development of history, more and more antibiotics have sprung up, and the fatal problems (drug resistance) caused by the large-scale application of antibiotics have gradually emerged seriously threatening people's health. Finding new types of antibiotics is an effective way to solve the problem of resistance. Antimicrobial peptide (ABP) originally refers to a class of basic peptides with antibacterial activity induced in insects. The molecular weight is about 2000-7000 and consists of 20-60 amino acid residues. According to its structure, it can be roughly divided into four categories: spiral, sheet, extended and ring. Some ABPs consist entirely of a spiral or sheet, while others have a more complex structure. The characteristic of extended peptides is the lack of recognizable structural motifs. However, they contain large amounts of specific amino acids such as arginine, tryptophan, glycine and histidine. The antibacterial mechanism of traditional antibiotics is that the antibiotics bind to the receptors of specific parts of the pathogen, so that the normal structure of the pathogen is destroyed or some biosynthesis is blocked, in order to achieve antibacterial or bactericidal effects. When the target site of its action changes, the antibiotic will lose its antibacterial effect, which is the main reason why bacteria develop resistance to antibiotics. The most common mechanism of action of ABP is to destroy the membrane potential, change the membrane permeability, and leak metabolites by binding to the cell membrane, directly destroy the pathogen cell membrane and kill bacteria, so it is not easy to develop drug resistance, Moreover, ABP also has the advantages of high antibacterial activity, wide antibacterial spectrum, many types, and a wide range of options, so it is considered to have broad application prospects in the pharmaceutical industry. In addition, a unique feature of many ABPs is their multiple mechanisms of action. For example, the antimicrobial peptide LL-37 that exists in the human body. The most common mechanism of action is to act on bacterial cell membranes, and it can also regulate inflammation and inflammation Anti-inflammatory immune response. The ability of ABP to function through multiple mechanisms and different pathways not only increases its antibacterial activity, but also reduces the tendency to develop drug resistance. Exercising effects through multiple channels can greatly reduce the possibility of bacteria acquiring multiple mutations at the same time, which makes ABP have a good therapeutic potential in drug resistance. In addition, because many ABPs act on the cell membrane sites of bacteria, bacteria must completely redesign their cell membrane structure to undergo mutations, and it takes a long time for multiple mutations to occur. In cancer chemotherapy, it is common to use multiple drugs with different mechanisms to limit the resistance of tumors. However, the use of multiple drugs increases the potential side effects and toxicity of chemotherapy. Therefore, a single ABP drug with multiple complementary mechanisms may have the same antibacterial effect with minimal side effects. Although there are currently a large number of natural ABPs that have excellent therapeutic effects, there are still many potential modifications that can be used to generate new ABPs. The global call for action to develop new antibacterial compounds to avoid the next antibacterial crisis.
查看详情
Advanced Version of New Antibiotics-Antimicrobial Peptide   In 1929, British bacteriologist Fleming discovered penicillin for the first time. Since then, Antibiotics have officially entered the stage of history. During the Second World War, penicillin became a very important strategic material to prevent war wounds from being infected. However, with the development of history, more and more antibiotics have sprung up, and the fatal problems (drug resistance) caused by the large-scale application of antibiotics have gradually emerged seriously threatening people's health. Finding new types of antibiotics is an effective way to solve the problem of resistance. Antimicrobial peptide (ABP) originally refers to a class of basic peptides with antibacterial activity induced in insects. The molecular weight is about 2000-7000 and consists of 20-60 amino acid residues. According to its structure, it can be roughly divided into four categories: spiral, sheet, extended and ring. Some ABPs consist entirely of a spiral or sheet, while others have a more complex structure. The characteristic of extended peptides is the lack of recognizable structural motifs. However, they contain large amounts of specific amino acids such as arginine, tryptophan, glycine and histidine. The antibacterial mechanism of traditional antibiotics is that the antibiotics bind to the receptors of specific parts of the pathogen, so that the normal structure of the pathogen is destroyed or some biosynthesis is blocked, in order to achieve antibacterial or bactericidal effects. When the target site of its action changes, the antibiotic will lose its antibacterial effect, which is the main reason why bacteria develop resistance to antibiotics. The most common mechanism of action of ABP is to destroy the membrane potential, change the membrane permeability, and leak metabolites by binding to the cell membrane, directly destroy the pathogen cell membrane and kill bacteria, so it is not easy to develop drug resistance, Moreover, ABP also has the advantages of high antibacterial activity, wide antibacterial spectrum, many types, and a wide range of options, so it is considered to have broad application prospects in the pharmaceutical industry. In addition, a unique feature of many ABPs is their multiple mechanisms of action. For example, the antimicrobial peptide LL-37 that exists in the human body. The most common mechanism of action is to act on bacterial cell membranes, and it can also regulate inflammation and inflammation Anti-inflammatory immune response. The ability of ABP to function through multiple mechanisms and different pathways not only increases its antibacterial activity, but also reduces the tendency to develop drug resistance. Exercising effects through multiple channels can greatly reduce the possibility of bacteria acquiring multiple mutations at the same time, which makes ABP have a good therapeutic potential in drug resistance. In addition, because many ABPs act on the cell membrane sites of bacteria, bacteria must completely redesign their cell membrane structure to undergo mutations, and it takes a long time for multiple mutations to occur. In cancer chemotherapy, it is common to use multiple drugs with different mechanisms to limit the resistance of tumors. However, the use of multiple drugs increases the potential side effects and toxicity of chemotherapy. Therefore, a single ABP drug with multiple complementary mechanisms may have the same antibacterial effect with minimal side effects. Although there are currently a large number of natural ABPs that have excellent therapeutic effects, there are still many potential modifications that can be used to generate new ABPs. The global call for action to develop new antibacterial compounds to avoid the next antibacterial crisis.
Dingxiangyuan's open medical data platform covers 7 application scenarios such as medicine, disease, and diagnosis
Dingxiangyuan's open medical data platform covers 7 application scenarios such as medicine, disease, and diagnosis
Dingxiangyuan's open medical data platform covers 7 application scenarios such as medicine, disease, and diagnosis Dingxiangyuan, a leading domestic digital medical and health technology company, announced the launch of a professional-level medical data open platform. This platform is the industry's first open data platform that can fully cover multi-scenario applications such as drugs, diseases, hospitals, departments, diagnosis and treatment, and medical information. It broke the current situation of internal data fragmentation in various institutions in the medical industry. At present, more than 400 pharmaceutical companies, financial insurance companies, and Internet companies including AstraZeneca, Alibaba Cloud, and Huatai Securities have become platform partners. It is reported that the Dingxiangyuan medical data open platform is supported by the core product medication assistant, Insight database, and Dingxiang doctor big data. Relying on 20 years of medical professional-level data accumulation, tens of millions of medical knowledge such as drug diseases, institutional data and tens of thousands of Clove Professional articles produced by the park copyright provide enterprise-level users with open data services based on standardized structured data. In the era of big data, medical care is gradually opening up, but the utilization rate of data within the medical industry is relatively low at this stage. Li Ning, head of product technology at Dingxiangyuan, said that under the premise of ensuring data security, the platform avoids the fragmentation of medical data and facilitates cross-medical organization collaboration, for the development and promotion of new drugs, optimizing clinical treatment plans, and preventing excessive treatment. Provide integrated data hard core support to make medical data play a greater value, thereby saving medical resources. For medical institutions, the Dingxiangyuan Medical Data Open Platform provides prescription review and timely discovery of potential unreasonable drug use problems; for pharmaceutical companies, the medical data open platform provides basic drug data construction; for the financial and insurance industry, the medical data open platform provides risk assessment for pharmaceutical companies , Medical insurance underwriting. In addition, the Dingxiangyuan medical data open platform also provides disease science services, medication instructions query services, and professional physician identity certification. Recently, Dingxiangyuan completed a new financing of US$500 million. With the promotion of the "medical-public" dual-core drive strategy, it is accelerating the accumulation of professional forces on the upstream supply side. The realization of the medical data open platform will also continue to accumulate new data and use the data for internal product innovation, enabling all participants in the medical system to connect and collaborate more closely.
查看详情
Dingxiangyuan's open medical data platform covers 7 application scenarios such as medicine, disease, and diagnosis Dingxiangyuan, a leading domestic digital medical and health technology company, announced the launch of a professional-level medical data open platform. This platform is the industry's first open data platform that can fully cover multi-scenario applications such as drugs, diseases, hospitals, departments, diagnosis and treatment, and medical information. It broke the current situation of internal data fragmentation in various institutions in the medical industry. At present, more than 400 pharmaceutical companies, financial insurance companies, and Internet companies including AstraZeneca, Alibaba Cloud, and Huatai Securities have become platform partners. It is reported that the Dingxiangyuan medical data open platform is supported by the core product medication assistant, Insight database, and Dingxiang doctor big data. Relying on 20 years of medical professional-level data accumulation, tens of millions of medical knowledge such as drug diseases, institutional data and tens of thousands of Clove Professional articles produced by the park copyright provide enterprise-level users with open data services based on standardized structured data. In the era of big data, medical care is gradually opening up, but the utilization rate of data within the medical industry is relatively low at this stage. Li Ning, head of product technology at Dingxiangyuan, said that under the premise of ensuring data security, the platform avoids the fragmentation of medical data and facilitates cross-medical organization collaboration, for the development and promotion of new drugs, optimizing clinical treatment plans, and preventing excessive treatment. Provide integrated data hard core support to make medical data play a greater value, thereby saving medical resources. For medical institutions, the Dingxiangyuan Medical Data Open Platform provides prescription review and timely discovery of potential unreasonable drug use problems; for pharmaceutical companies, the medical data open platform provides basic drug data construction; for the financial and insurance industry, the medical data open platform provides risk assessment for pharmaceutical companies , Medical insurance underwriting. In addition, the Dingxiangyuan medical data open platform also provides disease science services, medication instructions query services, and professional physician identity certification. Recently, Dingxiangyuan completed a new financing of US$500 million. With the promotion of the "medical-public" dual-core drive strategy, it is accelerating the accumulation of professional forces on the upstream supply side. The realization of the medical data open platform will also continue to accumulate new data and use the data for internal product innovation, enabling all participants in the medical system to connect and collaborate more closely.
2020华讯杯·法律写作竞赛圆满落幕
2020华讯杯·法律写作竞赛圆满落幕
发布时间 : 2021-01-15 10:52:10
2020华讯杯·法律写作竞赛圆满落幕 法律人工作的产出很大一部分是法律文书,所以法律文书的质量良窳就成为评判一位法律人能力的最主要标准。然而国内法学教育中的学生却非常欠缺专业法律写作能力的训练。有鉴于此,南京华讯举办华讯杯法律写作竞赛,期望通过此项活动,将美国法学院行之多年的法律写作训练与文化介绍到国内,以期对法律人的写作能力提升能贡献绵力。 本次竞赛从12月15日开始,历时近一个月,终于在1月13日圆满落幕,华讯邀请到获奖的三名学生前来参加2020华讯杯法律写作竞赛的颁奖典礼,工作人员接待了同学们后带领他们参观华讯的办公环境并简单介绍了华讯的成长历程。 由于疫情的关系,华讯总经理侯庆辰先生不能到场给同学们颁奖,但通过视频连线,侯律师对本次活动的成功举行发表了贺词:非常感谢参加本次华讯杯竞赛的学生,我们期许这次尝试只是初步播种,未来能够逐渐发芽茁壮,若华讯因此能对中国大陆法律人的能力养成可以有一点贡献,那将是我们无比的荣耀。 在和获奖同学的交流中,侯律师也对三位获奖作品做出了相应评价: 评王宁宁(一等奖) 紧抓议题,观点明确,逻辑清晰,完全符合法律论理文字的结构要求。 评唐梦璇(一等奖) 逻辑能力强。作者中文功底深厚。虽不完全照西式论理模式来写,但透过个人的写作能力仍充分展现出卓越的说理能力。 评王军昌(三等奖) 基本掌握论理结构,但若能在争点提出,还有每段论理,及每段小结与大结论的逻辑上再强化,将可以更好! 典礼的最后为同学们颁发了证书奖金并送上了鲜花。华讯希望能将华讯杯法律写作竞赛延续下去,每年都举办一届,为法学院的学生提供一个展现专业法律写作的平台。
查看详情
2020华讯杯·法律写作竞赛圆满落幕 法律人工作的产出很大一部分是法律文书,所以法律文书的质量良窳就成为评判一位法律人能力的最主要标准。然而国内法学教育中的学生却非常欠缺专业法律写作能力的训练。有鉴于此,南京华讯举办华讯杯法律写作竞赛,期望通过此项活动,将美国法学院行之多年的法律写作训练与文化介绍到国内,以期对法律人的写作能力提升能贡献绵力。 本次竞赛从12月15日开始,历时近一个月,终于在1月13日圆满落幕,华讯邀请到获奖的三名学生前来参加2020华讯杯法律写作竞赛的颁奖典礼,工作人员接待了同学们后带领他们参观华讯的办公环境并简单介绍了华讯的成长历程。 由于疫情的关系,华讯总经理侯庆辰先生不能到场给同学们颁奖,但通过视频连线,侯律师对本次活动的成功举行发表了贺词:非常感谢参加本次华讯杯竞赛的学生,我们期许这次尝试只是初步播种,未来能够逐渐发芽茁壮,若华讯因此能对中国大陆法律人的能力养成可以有一点贡献,那将是我们无比的荣耀。 在和获奖同学的交流中,侯律师也对三位获奖作品做出了相应评价: 评王宁宁(一等奖) 紧抓议题,观点明确,逻辑清晰,完全符合法律论理文字的结构要求。 评唐梦璇(一等奖) 逻辑能力强。作者中文功底深厚。虽不完全照西式论理模式来写,但透过个人的写作能力仍充分展现出卓越的说理能力。 评王军昌(三等奖) 基本掌握论理结构,但若能在争点提出,还有每段论理,及每段小结与大结论的逻辑上再强化,将可以更好! 典礼的最后为同学们颁发了证书奖金并送上了鲜花。华讯希望能将华讯杯法律写作竞赛延续下去,每年都举办一届,为法学院的学生提供一个展现专业法律写作的平台。
亚盛医药捷报频传-连获9项美国FDA孤儿药资格认证
亚盛医药捷报频传-连获9项美国FDA孤儿药资格认证
“孤儿药”又称为罕见病药,指用于预防、治疗、诊断罕见病的药品。在美国,罕见疾病是指患病人数少于20万人的疾病。自1983年以来,美国通过《孤儿药法案》的实施,给予企业相关政策扶持,以鼓励罕见病药品的研发,获得美国FDA孤儿药资格认定之后,意味着该药将享有临床试验费用税收减免、免除NDA申请费用、获得研发资助等,特别是该药物的该适应症批准上市后可获得美国市场7年独占权,因此获得FDA孤儿药认定也一直被视为重要的全球化创新实力指标之一。 近年来中国生物医药创新力量日益崛起,而作为一直坚持全球创新的领军企业-亚盛医药,自2020年以来捷报频传,连续获得9项美国FDA孤儿药资格认证,成为了中国生物医药企业中的佼佼者。 截止目前: FDA授予HQP1351一项孤儿药资格认定,适应症为慢性髓性白血病(CML)。HQP1351是一款新型口服第三代BCR-ABL抑制剂,对BCR-ABL以及包括T315I突变在内的多种BCR-ABL突变体有突出效果,用于治疗一代、二代TKI耐药的CML患者。 FDA授予APG-2575四项孤儿药资格认定,适应症分别为华氏巨球蛋白血症(WM)、慢性淋巴细胞白血病(CLL)、多发性骨髓瘤(MM)和急性髓系白血病(AML)。APG-2575是一款Bcl-2选择性小分子抑制剂,通过选择性抑制Bcl-2蛋白来恢复肿瘤细胞程序性死亡机制(细胞凋亡)。 FDA授予APG-115三项孤儿药资格认定,适应症分别为胃癌、急性髓系白血病(AML)和软组织肉瘤(STS)。APG-115是一种口服的、高选择性的小分子MDM2抑制剂,对MDM2具有高度结合亲和力,通过阻断MDM2-p53相互作用从而恢复p53的肿瘤抑制活性。 FDA授予APG-1252一项孤儿药资格认证,适应症为小细胞肺癌(SCLC)。APG-1252为亚盛医药自主研发的新型高效小分子药物,可通过选择性抑制Bcl-2及Bcl-xL蛋白修复细胞凋亡。 这些CML、WM、CLL、MM等罕见病的治疗都是全球层面目前尚未完全满足的临床需求。因此希望在获得FDA孤儿药资格认证之后相关政策的扶持能够有助于亚盛医药公司加快这几种药物的全球临床开发与产品上市,早日惠及更多的罕见病患者。
查看详情
“孤儿药”又称为罕见病药,指用于预防、治疗、诊断罕见病的药品。在美国,罕见疾病是指患病人数少于20万人的疾病。自1983年以来,美国通过《孤儿药法案》的实施,给予企业相关政策扶持,以鼓励罕见病药品的研发,获得美国FDA孤儿药资格认定之后,意味着该药将享有临床试验费用税收减免、免除NDA申请费用、获得研发资助等,特别是该药物的该适应症批准上市后可获得美国市场7年独占权,因此获得FDA孤儿药认定也一直被视为重要的全球化创新实力指标之一。 近年来中国生物医药创新力量日益崛起,而作为一直坚持全球创新的领军企业-亚盛医药,自2020年以来捷报频传,连续获得9项美国FDA孤儿药资格认证,成为了中国生物医药企业中的佼佼者。 截止目前: FDA授予HQP1351一项孤儿药资格认定,适应症为慢性髓性白血病(CML)。HQP1351是一款新型口服第三代BCR-ABL抑制剂,对BCR-ABL以及包括T315I突变在内的多种BCR-ABL突变体有突出效果,用于治疗一代、二代TKI耐药的CML患者。 FDA授予APG-2575四项孤儿药资格认定,适应症分别为华氏巨球蛋白血症(WM)、慢性淋巴细胞白血病(CLL)、多发性骨髓瘤(MM)和急性髓系白血病(AML)。APG-2575是一款Bcl-2选择性小分子抑制剂,通过选择性抑制Bcl-2蛋白来恢复肿瘤细胞程序性死亡机制(细胞凋亡)。 FDA授予APG-115三项孤儿药资格认定,适应症分别为胃癌、急性髓系白血病(AML)和软组织肉瘤(STS)。APG-115是一种口服的、高选择性的小分子MDM2抑制剂,对MDM2具有高度结合亲和力,通过阻断MDM2-p53相互作用从而恢复p53的肿瘤抑制活性。 FDA授予APG-1252一项孤儿药资格认证,适应症为小细胞肺癌(SCLC)。APG-1252为亚盛医药自主研发的新型高效小分子药物,可通过选择性抑制Bcl-2及Bcl-xL蛋白修复细胞凋亡。 这些CML、WM、CLL、MM等罕见病的治疗都是全球层面目前尚未完全满足的临床需求。因此希望在获得FDA孤儿药资格认证之后相关政策的扶持能够有助于亚盛医药公司加快这几种药物的全球临床开发与产品上市,早日惠及更多的罕见病患者。
Bayer's new anti-tumor drug BAY 2416964 received clinical approval in China
Bayer's new anti-tumor drug BAY 2416964 received clinical approval in China
Bayer's new anti-tumor drug BAY 2416964 received clinical approval in China According to Center for Drug Evaluation (CDE) announcement, Bayer's clinical application for BAY 2416964 tablets submitted in category 1 of chemical drugs was accepted by CDE on October 16 and received on December 17 two clinical trials have implied permission and are intended to be developed for advanced malignant tumours. This is the first time the product has been approved for clinical use in China, which means that this drug candidate is about to start clinical studies in patients with advanced malignant tumors in China. The Aryl Hydrocarbon Receptor (AHR) is a protein in immune cells, which can play an immunomodulatory role according to the integrated signals of microorganism and amino acid metabolism in human body. Because AHR is highly expressed in a variety of tumors and has immunomodulatory effects, modulators targeting AHR are considered to be one of the new types of immunotherapy. At the same time, this type of therapy is expected to be combined with other drug categories to improve the therapeutic effect. BAY 2416964 is a potent, highly selective and cross-reactive AHR inhibitor that can exert a variety of anti-tumor immunomodulatory effects. It can block the transcription of CYP1A1 mediated by different AHR agonistic ligands, and can directly interact with AHR, and can inhibit ligand-induced AHR transport to the nucleus. Studies have shown that BAY 2416964 with different doses and different dosing frequencies can inhibit specific tumor models. Bayer is currently carrying out an exploratory study on the human dose of BAY 2416964 in patients with advanced cancer. This is an open-label, phase 1, dose escalation and expansion study conducted for the first time in humans to evaluate the safety, tolerability, maximum tolerated dose, pharmacokinetics, and efficacy of the AHR inhibitor BAY 2416964 Kinetics and tumor response profile, etc. Senator Roy Blunt wrote this paragraph in the 《Cancer Development Report 2016》in the United States: "When a family is healthy, there may be many conflicts and problems. But if one of them has cancer, you have only one problem to deal with , and that's the cancer itself." I hope that the follow-up clinical development of this product will progress smoothly and bring a new treatment option to cancer patients as soon as possible.
查看详情
Bayer's new anti-tumor drug BAY 2416964 received clinical approval in China According to Center for Drug Evaluation (CDE) announcement, Bayer's clinical application for BAY 2416964 tablets submitted in category 1 of chemical drugs was accepted by CDE on October 16 and received on December 17 two clinical trials have implied permission and are intended to be developed for advanced malignant tumours. This is the first time the product has been approved for clinical use in China, which means that this drug candidate is about to start clinical studies in patients with advanced malignant tumors in China. The Aryl Hydrocarbon Receptor (AHR) is a protein in immune cells, which can play an immunomodulatory role according to the integrated signals of microorganism and amino acid metabolism in human body. Because AHR is highly expressed in a variety of tumors and has immunomodulatory effects, modulators targeting AHR are considered to be one of the new types of immunotherapy. At the same time, this type of therapy is expected to be combined with other drug categories to improve the therapeutic effect. BAY 2416964 is a potent, highly selective and cross-reactive AHR inhibitor that can exert a variety of anti-tumor immunomodulatory effects. It can block the transcription of CYP1A1 mediated by different AHR agonistic ligands, and can directly interact with AHR, and can inhibit ligand-induced AHR transport to the nucleus. Studies have shown that BAY 2416964 with different doses and different dosing frequencies can inhibit specific tumor models. Bayer is currently carrying out an exploratory study on the human dose of BAY 2416964 in patients with advanced cancer. This is an open-label, phase 1, dose escalation and expansion study conducted for the first time in humans to evaluate the safety, tolerability, maximum tolerated dose, pharmacokinetics, and efficacy of the AHR inhibitor BAY 2416964 Kinetics and tumor response profile, etc. Senator Roy Blunt wrote this paragraph in the 《Cancer Development Report 2016》in the United States: "When a family is healthy, there may be many conflicts and problems. But if one of them has cancer, you have only one problem to deal with , and that's the cancer itself." I hope that the follow-up clinical development of this product will progress smoothly and bring a new treatment option to cancer patients as soon as possible.
上一页
1
2
...
84

CONTACT

电话:+86 25 56673162 
E-Mail:service@chinaipic.com
地址:江苏省南京市江北新区江淼路88号腾飞大厦B座20层2001

公众号二维码

扫一扫,关注我们微博

公众号二维码

扫一扫,关注我们公众号

版权所有 © 南京华讯知识产权顾问有限公司      备案号:苏ICP备15002104号-1      网站建设:中企动力  南京